Lv7
5000 积分 2023-05-22 加入
NSCLC: Five trials to watch
1个月前
已完结
PT2.13.03 Spatial Multiomics Profiling Reveals Distinct Tumor Microenvironment and Therapeutic Targets in EGFR-Mutant NSCLC Transformed to SCLC
3个月前
已关闭
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial
3个月前
已完结
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial
3个月前
已完结
INSIGHT 2: a Phase II Study of Tepotinib Plus Osimertinib in MET -Amplified NSCLC and First-Line Osimertinib Resistance
3个月前
已完结
Shared lung and joint T cell repertoire in early rheumatoid arthritis driven by cigarette smoking
5个月前
已完结
Anti-CCP antibodies: the past, the present and the future
6个月前
已完结
Challenges in standardizing preimplantation kidney biopsy assessments and the potential of AI-Driven solutions
6个月前
已完结
Post-transplant recurrence of focal segmental glomerular sclerosis: consensus statements
6个月前
已完结
Focal Segmental Glomerulosclerosis
6个月前
已完结
皖公网安备34019202002308
